Table 1.
Baseline patient and lesion characteristics for all 8314 patients enrolled in the E-Five Registry stratified by diabetes status
| Characteristic | Non-DM | DM | p Value | NITDM | ITDM | p Value |
| (n=5593) | (n=2721) | (n=2039) | (n=682) | |||
| (n=6884 lesions) | (n=3455 lesions) | (n=2595 lesions) | (n=857 lesions) | |||
| Age (years) mean±SD |
62.31±11.34 (5593/5593) |
65.32±10.16 (2721/2721) |
<0.001 | 64.90±10.23 (2039/2039) |
66.57±9.85 (682/682) |
<0.001 |
| Female (%) | 19.8 (1106/5593) |
30.7 (834/2721) |
<0.001 | 28.2 (576/2039) |
37.8 (258/682) |
<0.001 |
| Unstable angina (%) | 33.1 (1851/5593) |
35.6 (969/2721) |
0.023 | 35.6 (725/2039) |
35.8 (244/682) |
0.926 |
| Prior MI (%) | 31.8 (1776/5593) |
33.0 (897/2721) |
0.271 | 32.0 (653/2039) |
35.8 (244/682) |
0.074 |
| AMI ≤72 hours* (%) | 14.8 (829/5593) |
11.9 (324/2721) |
<0.001 | 12.1 (247/2039) |
11.3 (77/682) |
0.586 |
| AMI <6 hours*† (%) | 5.2 (145/2810) |
3.1 (39/1263) |
0.003 | 2.8 (27/954) |
3.9 (12/309) |
0.347 |
| AMI 6–24 hours*† (%) | 5.3 (149/2810) |
4.4 (56/1263) |
0.278 | 4.1 (39/954) |
5.5 (17/309) |
0.339 |
| Prior PCI (%) | 25.5 (1426/5593) |
25.0 (680/2721) |
0.629 | 23.5 (480/2039) |
29.3 (200/682) |
0.003 |
| Prior CABG (%) | 7.3 (407/5593) |
8.1 (220/2721) |
0.199 | 7.2 (147/2039) |
10.7 (73/682) |
0.005 |
| Current smoker (%) | 25.4 (1419/5593) |
17.0 (463/2721) |
<0.001 | 18.0 (368/2039) |
13.9 (95/682) |
0.013 |
| Hypertension (%) | 63.7 (3564/5593) |
78.6 (2140/2721) |
<0.001 | 77.5 (1580/2039) |
82.1 (560/682) |
0.011 |
| Treated hyperlipidaemia (now or in past) (%) | 60.8 (3400/5593) |
67.7 (1843/2721) |
<0.001 | 67.7% (1380/2039) |
67.9% (463/682) |
0.962 |
| Moderate renal impairment (creatinine 140–220 mol/l)*† (%) | 3.6 (164/4540) |
7.0 (153/2180) |
<0.001 | 5.5 (91/1643) |
11.5 (62/537) |
<0.001 |
| Severe renal impairment (creatinine >220 mol/l)*† (%) | 1.0 (47/4540) |
3.3 (73/2180) |
<0.001 | 2.3 (38/1643) |
6.5 (35/537) |
<0.001 |
| B2/C lesions (%) | 60.0 (4128/6884) |
60.8 (2101/3455) |
0.418 | 61.0 (1585/2598) |
60.2 (516/857) |
0.678 |
| Lesion length (mm) | 18.49±10.54 (6881) |
18.55±10.74 (3451) |
0.790 | 18.57±10.84 (2595) |
18.49±10.46 (857) |
0.849 |
| Number of stents implanted | 1.19±0.48 (6884) |
1.18±0.47 (3455) |
0.242 | 1.17±0.46 (2598) |
1.19±0.50 (857) |
0.340 |
| Total stent length (mm) | 23.49±12.21 (6884) |
23.45±12.21 (3455) |
0.902 | 23.51±12.41 (2598) |
23.29±11.60 (857) |
0.645 |
| Number of lesions treated, mean±SD | 1.23±0.51 (5593/5593) | 1.27±0.56 (2721/2721) |
0.002 | 1.27±0.57 (2039/2039) |
1.26±0.51 (682/682) |
0.452 |
| Reference vessel diameter (mm) mean±SD | 2.95±0.47 (6884) |
2.90±0.46 (3455) |
<0.001 | NA | NA | – |
The time frame provided reflects the number of hours from the onset of AMI symptoms to the time of percutaneous coronary intervention.
Halfway through the E-Five Registry's enrolment, the case report form was modified to gather further detail about patients' baseline clinical characteristics, including renal function and the time between the onset of AMI symptoms and percutaneous coronary intervention. Thus, the denominator reflects the total number of patients in which the modified case report form was used.
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; DM, diabetes mellitus; ITDM, insulin-treated diabetes mellitus; MI, myocardial infarction; NITDM, non-insulin-treated diabetes mellitus; PCI, percutaneous coronary intervention.